Alzheimer's And Oncology Imaging Will Create Future Opportunities

Published
28 Aug 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
US$116.86
51.1% undervalued intrinsic discount
07 Aug
US$57.20
Loading
1Y
-40.8%
7D
-20.0%

Author's Valuation

US$116.9

51.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 Aug 25

Lantheus Holdings' valuation outlook remains stable as both the forward P/E ratio and revenue growth forecasts showed negligible changes, resulting in an unchanged analyst price target of $116.86. What's in the News Lantheus completed its $200M share repurchase program, buying back 3.43% of shares; a new $400M repurchase authorization is in place through 2027, replacing the expired prior plan.

Shared on07 May 25
Fair value Decreased 9.64%

Shared on30 Apr 25
Fair value Decreased 2.90%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 0.22%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 7.16%

AnalystConsensusTarget has decreased future PE multiple from 20.5x to 18.3x.